Atea Pharmaceuticals, Inc.

The company is a clinical-stage biopharmaceutical organization focused on discovering, developing, and commercializing orally administered antiviral therapies for serious viral conditions. Utilizing a proprietary nucleos(t)ide platform, it designs candidate treatments targeting single-stranded ribonucleic acid viruses. Its leading pipeline asset is a combination regimen of bemnifosbuvir and ruzasvir, currently evaluated in late-stage clinical trials for treating hepatitis C virus infections across multiple genotypes. Additionally, the business is advancing AT-587, an oral antiviral candidate intended to treat chronic hepatitis E virus infections, specifically targeting immunocompromised patient populations who currently lack approved targeted therapeutic options.

The enterprise conducts its clinical development activities on an international scale, running late-stage clinical trial programs with sites located across the United States, Canada, and various countries outside of North America. Its global studies evaluate diverse geographic populations to encompass a broad array of viral genotypes. While the excerpt mentions company staff monitoring these multinational trials under the name Atea, the provided text does not disclose a specific headquarters location.

Summary of the business section of Atea Pharmaceuticals's latest annual report, written by StockData.

“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.

“As of March 4, 2026, we had 55 full-time employees, including 19 employees with M.D., Ph.D.”